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INTRODUCTION 
 
Gastrointestinal Stromal Tumor (GIST) is the name given to a subset of 
uncommon neoplasms seen in the gastro-intestinal (GI) tract. Even though they 
comprise <1% of all GI tumors, GISTs are the commonest mesenchymal tumors 
of the gastrointestinal tract.
1
 
GISTs are seen through the length of the GI tract – from the esophagus to the 
rectum. 
Tumors that had been previously recognized as leiomyoma and leiomyosarcoma 
are actually CD117 (KIT) + tumors now called GIST.
2
 
 
The knowledge of GIST has been revolutionized by advances in its molecular 
understanding; however, this occurred only in the late 1990s and the early part 
of the 21
st
 century. The true incidence and global burden of this disease has 
often been underestimated in the past, but with more recently developed 
objective criteria to diagnose and classify GISTs, newer studies show a different 
picture. 
 
 
 
 
HISTORY 
 
In the 1940s, stromal tumors were mistakenly assumed to arise from cells of 
smooth muscle and were reported as GI leiomyomas, leiomyoblastomas, and 
leiomyosarcomas (True tumors of smooth muscle cells are extremely rare – 
examples include esophageal intramural leiomyomas and colorectal muscularis 
mucosae leiomyomas). 
 
However in the 1970s, electron microscopic examination exposed that only a 
minority of these tumors showed smooth muscle differentiation.
1
 these studies 
were backed up in the next decade by immunohistochemistry (IHC) – which 
showed that most of these tumors lacked the immunophenotypic features of 
smooth muscle differentiation.
1 
 
The nomenclature “GIST” was developed in 1983 by Mazur and Clark3, only as 
a descriptive term to define intra-abdominal malignancies that were, despite not 
showing carcinomatous features, also failed to exhibit typical features of either 
neural/smooth muscle cells. 
 
Herrera et al., in 1984 described a subgroup of these neoplasms that showed 
clear autonomic neural differentiation GANT (Gastrointestinal Autonomic 
Nerve Tumors).
4,5
 
 
IHC studies in the 90‟s showed CD34 expression in a substantial percentage of 
these neoplasms. It was originally hoped that CD34 would prove to be a feature 
unique to GISTs.  Disappointingly however, CD34 positivity was present in 
only half of all cases of GIST; furthermore, CD34 was not specific to GIST – it 
was expressed in many neural and smooth muscle tumors. Henceforth, CD34 
was considered as being neither sensitive nor specific in the distinction of GIST 
from other mesenchymal tumors.
6,7
 
 
The landmark advance in the understanding of GIST occurred in the late 1990s 
with the belief that these neoplasms showed histopathologic resemblances to the 
interstitial cells of Cajal (ICC), a specific cell type of the GI tract.
8 
ICCs are  
present in the myenteric plexus and muscularis propria and function as 
pacemaker cells that coordinate peristaltic movements of the GI tract by acting 
as an intermediate link between the smooth muscle cells of the intestinal wall 
and the autonomic nervous system. 
On electron microscopy, GIST cells and ICCs were found to have ultrastructural 
similarities, showing a combination of neural and myogenic differentiation, 
with both cell types expressing the KIT receptor tyrosine kinase (KIT RTK); 
consequently, it has been accepted that the precursor cells for both GISTs and 
normal ICCs are the same.
9,10
  
 
The molecular aspects of GIST pathogenesis was revolutionized in a study 
made by Hirota et al.
11
 in Japan in 1998. This group was interested in the role 
played by KIT in ICC and they went on to outline the association between GIST 
and KIT proto-oncogene mutations that initiated tumorogenesis by uncontrolled 
activation of the KIT signalling enzyme. 
 
Before 2000, therefore, there were no clearly defined, objective criteria to 
classify GIST. Similarly, many true GIST cases were classified by other names, 
such as leiomyomas, leiomyoblastomas, leiomyosarcomas, GANT 
(Gastrointestinal autonomic nerve tumor), Gastrointestinal pacemaker cell 
tumor, Plexosarcoma and Gastrointestinal neurofibrosarcoma. This makes the 
interpretation of publications before the year 2000 difficult.
1
 
 
 
 
 
 
 
 
 
 
REWIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TERMINOLOGY AND DEFINITION 
 
Gastrointestinal stromal tumors are defined as GI tract mesenchymal tumors 
that are specific, largely Kit (CD117)-positive which are Kit or platelet-derived 
growth factor receptor Alpha (PDGFRA) mutation-driven with typical  
histologic features such as spindle cell, epithelioid, and rarely pleomorphic 
morphology. GISTs encompass tumors with a wide spectrum of biologic 
potential at all sites of their occurrence.
12
 The range starts from tiny, mitotically 
inactive, clearly benign-looking tumors (which were previously often 
designated as leiomyomas). At the other end of the spectrum there are larger 
tumors many of which contain significant mitotic activity and are histologically 
sarcomatous, previously often called leiomyosarcomas. In the middle, nearly all 
variations of tumor size and mitotic activity occur, except that the small (<2 cm) 
tumors with high mitotic activity are very rare.
13
 Some, if not all authors 
maintain that most if not all GISTs should be considered having at least some 
potential for malignancy. GISTs are the most common mesenchymal tumor 
seen in the GI tract.
1
 
 
 
 
 
 
 
MOLECULAR PATHOLOGY 
 HISTOGENESIS 
 
Gastrointestinal stromal tumors originate from ICCs or their precursors. ICCs 
are intermediary cells, lying in-between smooth muscle cells that regulate 
motility of the GI tract and autonomic nerve function and the autonomic 
nervous system of the GI tract.
8
 They exhibit Kit and Kit-ligand (stem cell 
factor) positivity. ICCs are dependent cells, which are found around the 
myenteric plexus as well as in the muscular layer during the course of the 
gastrointestinal tract. Cajal cells are/contain a subclass of totipotent stem cell-
like cells that possess the ability to differentiate into smooth muscle cells when 
Kit signalling is disrupted.
14
  
 
Fig.1 Cajal cell maturation and consequent GIST formation 
 
It has been shown that, in mice with Kit or stem cell factor deficiency intestinal 
dysmotility due to lack of ICCs.
15
 Transgenic studies done on mice with 
introduced constitutional KIT-activating mutations was shown to cause ICC 
proliferation leading to GIST formation. 
16,17
 Kitamura and Hirota first reported 
KIT mutations in GIST in 1998 based on similarity to the mast cell system, 
wherein deficiency of KIT caused dearth of mast cells; and activating mutations 
was noticed to produce mast cell neoplasia.
18
 
 
 
 
 
PATHOGENESIS 
 
Mutually exclusive mutations in Kit or PDGFRA receptor tyrosine kinase 
proteins are seen in >80% of GISTs, which are principal in the pathogenesis of 
sporadic GIST. These somatic mutations are present only in cells of the tumor 
tissue, while the analogous constitutional mutations of familial GISTs, (which 
are inheritable) are present throughout all cells of the body. These mutations 
produce functional alterations in the Kit proteins and PDGFRA proteins, and 
lead to activation.
18.19
 The KIT and PDGFRA genes code for the 
correspondingly termed homologous receptor tyrosine kinase proteins. They 
(KIT and PDGFRA genes) are located pericentromerically at Chromosome 
4q12, most probably having evolved as an ancestral gene duplication.
20
 The 
analogous Kit/ PDGFRA proteins have essential features of type 3 receptor 
tyrosine kinases.
21
 Activating KIT/PDGFRA mutations allow phosphorylation 
of the receptor TKs, activating downstream effectors. The final result of this 
activation is increased cellular proliferation and decreased apoptosis, 
culminating at neoplastic change (The exact genetic events are currently 
unknown) .
18, 19 
Other genetic alterations have been identified in GISTs apart 
from receptor tyrosine kinase mutations. In one condition, there is possibly 
early tumor suppressor gene loss in chromosomes 14q and 22q, possibly 
pathogenetically important (Identification of specific genes have not yet been 
reported).
22,23
  
 
 
KIT MUTATIONS 
 
Sporadic GISTs show KIT mutations in four different regions of the gene. The 
most common is exon 11 mutation, followed by exon 9, exon 13, and exon 17 in 
decreasing order. The majority of Kit-mutant proteins are sensitive to the 
tyrosine kinase inhibitor imatinib. But, exon 17 Kit-mutants in GIST show 
primary resistance. Also, exon 9 mutants have been found to be less sensitive 
than exon 11 mutants.
24
. In-frame deletions of one to several codons account for 
60-70% of KIT exon 11 mutations.
25
 KIT exon 11 missense point mutations are 
seen in 20-30% of GISTs. Exon 11 missense mutations in stomach GISTs have 
been shown to have better prognosis than tumors with exon 11 deletions.
26,27
   
 
 
Fig.2  KIT receptor mutations 
 
 
 
PDGFRA MUTATIONS  
 
PDGFRA mutations occur in 3 reigions, forming GISTs. The commonest is 
exon18, followed by exon12 and exon14.
28
 Gastric GISTs are more associated 
with PDGFRA mutations, usually showing epithelioid histopathology. Most 
(>80%) of PDGFRA mutants are missense mutations involving exon 18.This 
mutation shows imatinib resistance. 
 
 
EPIDEMIOLOGY 
 
Population-based studies in Iceland and Sweden show the incidence of GIST to 
be 11 per million - 14.5 per million.
29,30
. GIST prevalence is expected to be 
higher, as a high proportion of patients not succumb to the disease. GISTs show 
predilection for adults > 50 years of age. The median ages in most international 
series are slightly around 60 years. No clear sex predilection has been observed, 
however, men are slightly more suspectible to malignant GISTs. GIST patients 
who are less than 40 years of age account for 5-20% of cases in different sites. 
These tumors are extremely rare in the pediatric age group (<1%), where they 
mainly affect female young adults, are usually gastic GISTs, and often have 
epithelioid histopathology. Pediatric tumors may possess a dissimilar 
pathogenesis than adult GISTs: KIT /PDGFRA mutants are usually absent.
31,32
  
 
GISTs are seen from the esophagus to the rectum. They are most commonly 
Gastric (60%), jejunoileal (30%), duodenal (5%), and colorectal (<5%).
1,13
 Only 
few cases (<1%) have been reported in the esophagus and appendix. 
Gastrointestinal stromal tumors can occur in the mesentery, omentum and 
retroperitoneum, where they could be metastatic or possibly detached from their 
GI tract origin. However, a small number of apparent primary tumors have been 
reported in these sites.
33,34,35
 A few GISTs also are diagnosed as disseminated 
abdominal tumors.  
 
 
CLINICAL FEATURES 
The clinical features associated with a GIST depend on various factors, such as 
the location/size of tumor/tumor behaviour. Gastrointestinal tract bleeding is 
commonest presentation of GIST in international literature.
1,2
 This may 
manifest as hematemesis, melena or chronic blood loss. Tumor rupture, gastric 
outlet/intestinal obstruction, or intraperitoneal bleeding can simulate an acute 
abdomen. Smaller GISTs are often diagnosed incidentally during surgery, 
imaging, or endoscopy; the latter applies especially to situations where mass 
screening for carcinoma stomach is being practiced (Such as Japan). 
Clinical features associated with GIST are similar to the pathology associated 
with the anatomic location of the primary tumor.  
Approximately 25% of stomach and 50% of small bowel GISTs are malignant 
on clinical grounds. Metastases are usually hepatic or peritoneal; rarely skeletal, 
lymph nodal and pulmonary.
36
 Metastases can develop late, even more than a 
decade after the curative surgical intervention, thus necessitating long-term 
vigilance.  
 
 
Fig 3. Typical appearance of a gastric GIST 
 
Gastric GISTs initially start in the submucosa and usually grow slowly. Smaller 
tumors can manifest as incidental findings on investigations, although they 
occasionally may ulcerate and cause impressive bleeding. Larger neoplasms can 
cause symptoms of loss of appetite and weight, pain, early satiety, and 
haemorrhage. Symptoms of Gastric Outlet Obstruction (GOO) may be present 
in lesions close to/involving the pylorus. An abdominal mass may be palpable. 
Metastasis is by the hematogenous route, often to liver and/or lung, although 
positive lymph nodes are occasionally seen in resected specimens.  
Gastrointestinal stromal tumors comprise up to 15% of all small bowel 
malignancies. Most patients present in their fifth or sixth decade of life. GISTs 
are also a rare cause of primary mesenteric/peritoneal neoplasms. They may 
present as an abdominal mass with or without secondary symptoms.
33
 
 
 
DIAGNOSTIC AND INVESTIGATIVE MODALITIES 
 
Diagnosis is usually made by non-invasive methods such as Trans abdominal 
Ultrasound (USG) or Contrast Enhanced Computed Tomography (CECT). 
CECT is invaluable in both primary disease as well as metastatic staging.
1
 
Metastases to the liver are well detected by CECT; however, Magnetic 
Resonance Imaging (MRI) can also be used for the same. 
Gastric GISTs are evaluated by upper GI scopy. They present as a smooth 
projections in the stomach covered by mucosa, which may show bleeding 
/ulceration.
37
 The majority of GISTs arise submucosally and may grow in an 
endophytic manner. Endo Ultrasound (EUS) is also useful in evaluation of 
gastric tumors.  
 
Fig.4 Gastric GIST on CECT 
 
CT scanning provides good imaging of the tumour size as well as loco-regional 
involvement. Smaller sized neoplasms appear well marginated and are hypo 
dense on plain CT. Contrast studies show the enhancement to be homogeneous. 
GIST on CT may resemble other malignancies such as bowel lymphoma. Many 
Larger GISTs show cystic changes, surrounded by tumor enhancement on 
CECT. The tumor may undergo necrosis, causing fistula formation with the 
bowel and/or intratumoral calcified areas.
 
 
 
 
Fig 5. Jejunal GIST on CECT 
 
Positron Emission Tomography, especially in combination with CT/MRI (PET-
CT/PET-MRI) has a role in the investigation of GISTs, especially in a the event 
of metastasis/recurrence, or to assess response to Imatinib therapy, but the exact 
role that these modalities play will be seen in the future, as the results of many 
ongoing trials come to light. 
Preoperative biopsy is amenable only to superficial stomach lesions; via upper 
GI scopy.
1
 Biopsies can be taken percutaneously, but this can theoretically 
cause seeding of the tumor into the peritoneum, or even rupture of the tumor. It 
should be done only in cases of certain inoperability or when different treatment 
may be required (e.g. the swelling proved to be a lymphoma or germ cell 
tumor). Peroperative frozen section is rarely indicated; as a diagnosis is likely to 
be given only by a highly experienced pathologist.
36
 
 
Fig. 6 Endoscopy of a gastric GIST with ulceration 
 
  
 
 
 
 
 
HISTOPATHOLOGY 
 
GROSS APPEARANCE 
 
Smaller GISTs usually manifest as solid subserosal, intramural, or rarely 
polypoid masses, lying intraluminally. Most large GISTs form external tumors, 
which may occasionally be pedunculated masses attached to outer aspect of GI 
tract, with muscle layer involvement. Larger tumors often show cystic changes 
centrally. Others can depict a diverticulum-like appearance, due to 
communication of the external tumor with the bowel lumen by a fistulous tract. 
A few GISTs may show an asymmetric hourglass-like shape with a larger 
external and smaller internal component.  
  
Fig. 7 Cut section of a small bowel GIST 
 
HISTOPATHOLOGY OF STOMACH GISTs 
 
70% of stomachs GISTs are sub classified histopathologically into 8 subtypes - 
4 related to spindle cell and 4 related to epithelioid tumors. These subtypes form 
a spectrum.
26
  
GISTs with Sclerosing spindle subtype are paucicellular tumors with low 
mototic activity. Palisading-vacuolated subtype, which is the most common 
among stomach GISTs exhibits prominent perinuclear vacuolization and nuclear 
palisading, similar to peripheral schwannomas. These tumors can reach sizes > 
10 cm despite having low mitotic counts. Densely packed, uniformly placed 
spindle cells without significant atypia and mitotic activity are seen in the 
Hypercellular subtype (Figure 2, C). Significant mitotic activity (usually >20 
per 50 HPFs) and diffuse atypia is seein in the Sarcomatous spindle cell 
subtype.
2
 
 
Fig. 8 Palisaded vacuolated spindle cell gastric GIST 
Sclerosing epithelioid variant show low mitotic rate, however focal atypia and 
multinucleation are seen. The have polygonal tumors cells arranged in a 
syncytial pattern. 
Dyscohesive epithelioid subtype exhibit a lacunar space surrounding the 
epithelioid cells, which have sharp cell borders. Hypercellular epithelioid 
subtype show closely arranged cells and low mitotic activity.  Sarcomatous 
epithelioid also are highly cellular, but showing striking mitotic activity, often > 
20 per 50 HPFs.
2 
 
Fig.9 Sarcomatous epitheloid gastric GIST 
 
HISTOPATHOLOGY OF SMALL BOWEL GISTs 
 
Small bowel GISTs do not show individual histopathological subtypes 
appreciated in their stomach counterparts. The majority of small bowel GISTs 
are composed of spindle cells, and 40-50% of them show distinct, eosinophilic 
extracellular collagen fiber aggregates that stain positively for PAS. These 
aggregates are named „skeinoid fibers‟.39 Presence of skenoid fibres is a 
favorable prognostic feature, they are usually seen in nonmalignant GISTs.
40
  
 Fig. 10 Small intestinal GIST rich in skeinoid fibers 
 
Despite the typical malignant course, only a few small bowel GISTs exhibit 
sarcomatous features.  High mitotic activity is also uncommon. Epithelioid 
tumors are associated with malignant GISTs.  
 
 
 
 
 
 
HISTOPATHOLOGY OF OTHER GISTS  
Non-gastric, non-intestinal GISTs are usually show spindle cell histology. Rare 
appendiceal and some colonic GISTs show skeinoid fibers resembling small 
bowel tumors. Skeinoid fibers are not seen in rectal GISTs, which bear more 
resemblance to gastric tumors, with a  hyalinized-calcified or palisading nuclear 
pattern. Rectal GISTs may be clinically indolent, again, similar to stomach 
tumors.
41
  
Omental GISTs may show spindle cell and epithelioid features, similar to 
stomach GISTs, while mesenteric GISTs sometimes show skeinoid fibers and 
resemble the small bowel tumors.
33
 Therefore, it is possible that omental and 
mesenteric GISTs represent tumors that may have detached from their GI origin 
(stomach and small bowel respectively) during their development. 
 
IMMUNOHISTOCHEMICAL FEATURES OF GIST 
Kit (CD117) positivity is a key feature of GIST, seen in > 95% of cases. A 
positive repot of CD 117, while being a chief defining principle for GIST, is no 
longer regarded as a categorical prerequisite. As mentioned earlier, Kit 
manifestation in GIST is not the result of a mutation, but is constitutional. CD34 
and nestin are also expressed in GISTs. Smooth muscle indicators (eg. SMA) 
may be positive but GISTs are generally desmin-negative. Positive neural 
markers, such as S100 is rare. Keratin 18, rarely keratin 8, may be expressed.  
 KIT (CD117) 
 
Global, strong KIT positivity in seen in GISTs, which appears pancytoplasmic. 
Membrane staining is better seen in epithelioid GISTs. Certain epithelioid 
gastric GISTs less may be weakly positive/negative for Kit - these exhibit 
PDGFRA mutations.  
The best KIT antibodies presently available for paraffin sections of formalin-
fixed tissue are polyclonal antibodies. Most monoclonal antibodies show 
inconsistent reaction with GISTs. Although definitional, Kit positivity is not 
diagnostic of GIST. Various other tumors such as mastocytomas, small cell lung 
carcinomas, seminomas, granulocytic sarcomas may show KIT positivity. More 
specifically, neuroblastomas, angiosarcomas, metastatic melanomas, Ewing 
sarcomas and clear cell sarcomas represent abdominal tumors that may be KIT 
positive.
42
  
 Fig. 11 KIT immunostaining in GIST 
 
PDGFRA  
 
Scarce data on PDGFRA expression is presently available. The reliability of 
antibodies on paraffin sections is also dismal. However, PDGFRA still can be 
used as a diagnostic immunohistochemical marker.
43 
 
OTHER GIST MARKERS 
 
 Protein kinase theta has has been suggested as an IHC tool, as well as a 
therapeutic kinase target for GIST.
44
 However, positive staining is usually weak 
and less characteristic than Kit positivity.
2
  
DOG1, a new gene, termed as it was „„discovered on GIST‟‟ also is expressed 
in GIST and is not present in non-GISTs.
45
  
80% of stomach and 50% of bowel tumors show CD34 positivity. CD34 is a 
hematopoietic precursor cell antigen present in fibroblasts, endothelial cells, and 
related malignancies. Esophageal and rectal GISTs are nearly unfailingly CD34 
positive (95-100%). 
26
 
 
 
 
 
 
 
 
 
 
 
 DIFFERENTIAL DIAGNOSIS 
 
Smooth muscle malignancies, desmoids, neural sheath tumours, inflammatory 
myofibroblastic tumors and undifferentiated sarcomas among other tumors are 
often mistaken for GISTs. These neoplasms almost always show Kit negativity, 
and most of them have their own specific immunohistochemical markers. The 
following table shows histological differential diagnoses for GISTs. 
 
 
Fig. 12 Histologic differential diagnosis of GIST 
 
PROGNOSIS 
 
GISTs, at all sites of their occurrence form a continuum in biologic potential. 
Older data on smooth muscle tumors of the GI tract(including GISTs in the 
current jargon) have created an illusion by distinctly separating benign and 
malignant tumors. As there were no specific separating standards, it is 
problematic to understand the predictive parameters based on older studies. 
Cancer centers have heightened emphasis on clinically malignant tumors – due 
to referral bias. Newer large studies (with >500 cases each) have more clearly 
delineated the prognostic parameters.
26,27,36
 These data from the pre-imatinib era 
shed light on the natural history of GISTs and may help in adjuvant treatment 
application. 
The most dominant criteria for evaluation of GIST biologic potential are tumor 
dimensions and mitotic activity. Mitotic activity is stated per 50 HPF (high 
power fields – 40x) (totaling 5 mm2).26,27 This corresponds to 25 fields with a 
x40 magnification using newer wide-field microscopes. Size and mitotic rate 
parameters should always be incorporated in the pathology report. There is a 
well-established relationship between these parameters and tumor behavior 
based on several large clinico-pathologic studies. There is greater biologic 
potential of small intestinal versus stomach GISTs, the reasons for which are 
unknown.  
The following table depicts prognostic criteria developed after analysis of large 
studies.
26,27
 Lesser data on GISTs of rare sites, such as the esophagus is 
currently avalable. However, in terms of prognosis, tumors at these sites should 
probably be assessed with guidelines similar to small intestinal GISTs. 
 
Fig. 13 Prognostic grouping of GIS 
 
STAGING (TNM)  
 
A new TNM staging system for GIST has been developed by the AJCC for 
GIST.
13
 This is the first time that a TNM staging is being used for GIST. 
This new AJCC staging is an adaptation the Miettinen and Lasota (AFIP) risk 
table.
26,27 
 
The AJCC staging schemes use "TNM" - it stands for Tumor Node Metastasis.   
  
 T1 ≤ 2 cm 
T2 > 2 cm ≤5 cm 
T3 > 5 cm ≤10 cm 
T4 > 10 cm  
 N0 No lymph nodes  
N1 Presence of lymph nodes 
 M0 No metastasis 
M1 Metastasis present 
  
Low grade  : ≤5 mitoses/HPF 
High Grade: >5 mitoses/50 HPF.
13 
Given below is the stage grouping, done separately for gastric and small 
intestinal GISTs. 
 
 
Fig. 14 TNM Stage grouping 
 
 
Grading, used in sarcomas, was earlier used for GISTs, but is not ideal , as the 
mitotic rates seen in GISTs is much lower. Also GISTs are more malignant at 
lower rates of mitoses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT 
 
TREATMENT OF EARLY STAGE GISTs  
 
Definitive surgery remains the backbone of treatment for localized, primary 
GIST. Surgical removal of advanced GIST should be performed only if there is 
an acceptably low risk of functional deficit. Large GISTs in areas that would 
pose a challenge to total resection (e.g., pancreatic bed invasion), should be 
considered unresectable; and these patients should get preoperative imatinib, 
and strict regular follow up should be employed. For these cases, PET scanning 
is very valuable for early assessment of therapeutic response. Imatinib 
minimizes the risk of disease progression, which may put the patient at risk for 
further tumor growth and invasion. After the maximal response (generally by 4-
6 months), decisive surgical resection could be performed.
1
  
 
 Fig 15. Intraoperative picture of a small intestinal GIST 
 
Regarding the surgical approach to GIST resection, it must be evoked that 
locoregional lymph nodal involvement is rare, and so lymph node dissections 
are rarely indicated. GISTs sometimes have a fragile pseudocapsule; tumor 
rupture during surgery must be avoided, failing which, peritoneal dissemination 
can occur.
46
 The resected margins of the specimen should be oriented and 
examined, and biopsies from various areas of the tumor should be examined by 
the pathologist. 
In cases of limited, early stage GIST, a R0 resection should be performed. 
Preoperative Imatinib treatment can be given if complete resection is not 
possible.
47
 Post-operatively, patients with poor prognostic criteria (mentioned 
earlier) should recieve adjuvant imatinib.
47,48 
  
MANAGEMENT OF UNRESECTABLE,METASTATIC,  
OR RECURRENT GISTs  
Before the introduction of tyrosine kinase inhibitors such as imatinib, which 
became known as “targeted therapy”  for treatment of GISTs, conventional 
cytotoxic chemotherapy was used, but with generally fruitless results. Rates of 
response to a variety of chemotherapeutic drugs for patients with GISTs were in 
the region of a paltry 0-5%.
49,50
 Even intraperitoneal chemotherapy
51
 was tried, 
again unsuccessful (Only few cases of GIST remain limited to the peritoneal 
surface).  
Other loco-regional procedures, such as hepatic artery embolization or 
chemoembolization were also tried, albeit with little success. Limited 
progression-free survival was seen in some patients, but the benefit was usually 
for months rather than years, and this too lost favour in the management of 
metastatic/unresectable GIST patients.
52,53
 
GIST showed pronounced resistance to chemotherapy – this was shown to be 
partly by the greater levels of P glycoprotein which is produced by the MDR - 1 
gene(multi-drug resistance 1) and the MRP - 1 (multi-drug resistance protein 
1).
54
   
It has been hypothesized that chemotherapeutic drugs are prevented from 
reaching intracellular therapeutic levels in the GIST cells by these cellular 
efflux pumps.  
Radiotherapy too has a very limited role to play in management of 
metastatic/unresectable GISTs - therapeutic doses of radiotherapy delivered to 
intrabdominal tumors generally result in more morbidity than any benefits. 
However, newer radiotherapy modalities such as IMRT (Intensity-Modulated 
Radiotherapy) can be used for palliation in specific patients. (eg. focal 
bleeding/pain control/bulky liver metastasis etc.) 
Evidently, patients with metastatic/unresectable GIST had dismal prognosis 
before the introduction of mechanism-based molecularly targeted therapy. In 
patients with metastatic or recurrent GISTs, the majority of studies documented 
very poor survival rates, with mortality from disease progression usually 
occurring within 2 years after the first recurrence or metastasis.
36,49
 
 
TARGETED THERAPY FOR GIST: IMATINIB  
Imatinib mesylate (Gleevec, STI-571) was created in the 90s by Lydon and 
Druker, initially aimed for the treatment of hematologic malignancies, such as 
CML.
55,56
 Imatinib is a 2 - phenyl-amino-pyrimidine derivative, acting by 
inhibiting many tyrosine kinases. It acts by occupying the functional TK site, 
and leads to a reduced activity by blocking entry of substrate to the kinase site.
55
 
(Figure below) Imatinib was shown to be very efficacious and it is currently a 
record-holder, as the drug to be approved quickest by the FDA. Approximately 
90 % of GISTs harbor an activating mutation in the KIT or PDGFR alpha 
oncogene known to confer imatinib sensitivity.  Several trials have revealed that 
imatinib response mainly depends on the status of KIT/PDGFR alpha 
mutant.
55,56 
 
 
Fig 16. Mechanism of action of imatinib 
 
Objective response with imatinib is achieved in > 50% advanced GIST; 6-
months progression free survival (PFS) rate of >75 % in patients with advanced 
GISTs could also be achieved. Also, even in patients with stable disease, long-
term tumor control could be achieved.
36,47,48
  
Mulitple studies, including EORTC-62024, RTOG and the ACOSOG, amongst 
others have shown tremendous benefit from Imatinib in the management of 
GIST.
48 
Imatinib is used at a starting dose of 400 milligrams / day. For cases with KIT-
exon9 mutants, the start dose is 800mg/day.
47
 Imatinib plasma level studies 
being conducted to perfect the dose. Imatinib has a relatively good side effect 
profile, although most toxicities are dose-related. Uninteruppted treatment must 
be followed, as a break is associated with rapidly progressive disease. The ideal 
period of adjuvant imatinib therapy is currently unknown.
1,47 
Resistance to imatinib happens usually between 18-26 months. Other simiilar 
molecules have also been developed. Sunitinib, another inhibitor of TK is 
exquisitely efficacious in exon9 ckit mutants, which generally are poor  
responders to imatinib.  
To monitor disease response to Imatinib, various imaging modalities were 
utilized, even during drug development itself. Imatinib was found to 
dramatically affect tumor avidity for 
18
FDG, as seen on a PET scan. Reduced 
tumor avidity for 
18
FDG could be detected on a PET scan even 24 hours-post an 
imatinib dose, much before a CT scan. Correlation with positive response to 
imatinib as well as documention of imatinib resistance was noted in studies. 
Thus, 
18
FDG-PET functional imaging of GIST represents a useful technique for 
early assessment of response to treatment with imatinib.
57,58
 
 
 Fig. 17 Response to imatinib as imaged by 
 18
FDG-PET (above) and CT scans 
(below) 
 
Although PET scans showed metabolic responses in the majority of patients, 
Objective responses (using RECIST criteria) were lacking. Studies have shown 
that a tumor shrinkage of >10% or a reduced tumor density of 15% on CT 
scanning before and after 60 days of imatinib identified cases with good 
metabolic response. This new CT criteria is called Choi criteria
59
, and it helps in 
identification patients who have a lengthier period to progression. The Choi 
criteria has now been proved to be advantageous over RECIST.
59,60
 
 
 
 
 
RESISTANCE TO IMATINIB 
Imatinib resistance may be primary and presents itself as rapid disease 
progression in spite of initial imatinib treatment; however this is seen in < 20% 
of patients. More commonly, clonal evolution of a resistant GIST is detected >1 
year of established disease-free interval. Many foundations of imatinib 
resistance in GIST have been described,
61,62
 similar to those mechanisms 
demonstrated in CML.  
The most commonly seen mechanism of imatinib resistance is the appearance of 
new mutations at a discrete region of the KIT-kinase coding area.
61,62
 It is 
possible  that previously double-mutant tumor cells could slowly grow out 
under the stimulus of chronic imatinib selection pressure, similar to the rise of 
antibiotic-resistant strains of bacteria. To deal with the double-mutant KIT 
molecular target, newer drugs such as sunitinib malate, which is a structurally 
dissimilar kinase inhibitor have been used for differential activity against the 
mutant. Sunitinib also exhibits potent antiangiogenesis activity as it targets 
several tyrosine kinases for inhibition, including the VEGF receptor in addition 
to PDGFR. Phase I and II trials of sunitinib showed that many patients 
experienced reduction of GIST activity on 
18
FDG-PET imaging, and a large 
group achieved disease. However, only a minority of patients actually 
experienced objective response• by RECIST criteria.
84
 A large trial validated 
that sunitinib definitely improved the progression-free survival of patients 
following failure of Imatinib due to resistance/intolerance.
63
  
Rare instances of Sunitinib resistance have also been reported, newer drugs such 
as Sorafenib are promising and under investigation. 
 
PEDIATRIC GIST  
 Pediatric GISTs are rare tumors and most data has come from case reporting.  
They are more commonly seen in girls, above 10 years of age. GIST mutations 
in this population have still not been described. The majority are Gastric GISTs, 
showing multifocal tumors. ). Nodal metastases, recurrence at previous site are 
more common than in adults. However disease progression is less aggressive 
compared to adults. 
64-68
   
 
CARNEY TRIAD  
Carney Triad denotes two out of the following three tumors
69
 
 GIST 
 Chondromas of the lung 
 Paragangliomas at non-adrenal sites 
<40 cases of Carney triad have been published.   Females are usually affected 
(>80%), and the initial malignancy appears <30 years of age in 90% of cases.  
The first malignancy is typically a stomach GIST.    
These GISTs exhibit multi-focality. Duodenal tumors can occur.  Disease 
aggression is lesser than sporadic cases, with comparatively better prognosis.
70  
 
FAMILIAL GIST  
Occasionally GIST may run in families due to. This rare entity (<20 published 
cases) occurs secondary to germline mutations of KIT/PDGFRA genes. Patients 
develop the tumor at a younger age, usually in the third and fourth decade of 
life. It is an autosomally dominant condition. 
KIT mutants show various other features, such as skin pigmentation, nevus, 
urticarial-pigmentosa, and  achalasia may be seen.  
PDGFRA mutant has not shown to have other symtoms.
71
   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
STUDY DESIGN 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
AIM : 
The understanding of GIST is evolving; and the specific criteria to define and 
classify GISTs have come into the mainstream only after 2000. This, along with 
its rarity makes our knowledge about GISTs relatively limited. The lacunae are 
more expressed in India, where there have been very few clinico-pathologic 
studies done. 
The main aim of the study is to evaluate the epidemiology, clinical 
presentations, investigations, histopathologic features and treatment modalities 
of GIST.  
The study was conducted by a retrospective analysis of patients who were 
admitted in all the surgical units of the Department of General Surgery and in 
the Department of GI Surgery, Govt. Stanley Medical College and Hospital, 
Chennai between October 2010 and October 2012 
 
 
 
 
 
OBJECTIVES: 
1) To study the epidemiology of GIST 
2) To study the clinical presentation of GIST 
3) To study the various treatment modalities of GIST 
4) To study the histopathology and grading of GIST 
5) Review of literature of GIST 
 
Inclusion criteria: 
1) Histopathologically proven case of GIST 
 
Exclusion criteria: 
 None 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS: 
 Patients admitted in our hospital from October 2010 to October 2012 will 
be enrolled in the study. The following materials and methods were used:  
o Clinical history 
o General and systemic examination 
o Imaging modalities (USG/CECT) 
o Upper GI Endoscopy 
o Surgery 
o Gross pathology 
o Microscopic histopathology 
o Immunohistochemistry (CD117) 
 
A total of 32 patients who were histopathologically diagnosed as GIST were 
included in the study. 
The study design is as follows. 
1. All the patients are subjected to detailed history taking and clinical 
examination  
2. Patients underwent imaging modalities – Ultrasound (USG) and Contrast 
Enhanced Computed Tomogram (CECT), as part of diagnostic and 
staging workup and the findings were noted. 
3. If indicated, the patients underwent Upper GI Scopy (Gastric GISTs) 
4. Patients were subjected to appropriate surgery. 
5. Intraoperative findings were studied. 
6. The tumor specimen was sent to the Department of Pathology to study the 
Gross, Microscopic and Immunohistochemical pathology. 
7. All the findings were tabulated in a master chart, and data analysis was 
done. 
8. The results of the study were compared to existing Indian as well as 
international data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
AGE DISTRIBUTION: 
AGE GROUP NO. OF PATIENTS(n=32) 
20 - 29 YRS 1 
30 – 39 YRS 3 
40 – 49 YRS 7 
50 – 59 YRS 8 
60 – 69 YRS 10 
70 – 79 YRS 3 
 
 
 
Majority of patients were above 50 years of age (21/32), with peak incidence 
between the 60-69 years of age (10 patients) 
 
PRESENTATION 
 
 
MODE OF PRESENTATION NO. OF PATIENTS(n=32) 
ELECTIVE 25 
EMERGENCY 7 
 
 
 
 
 
Out of 32 patients, 25 (78%) presented electively in the OPD, while 7 (22%) 
presented as an acute emergency. 
 
 
SEX DISTRIBUTION: 
 
SEX NO. OF PATIENTS(n=32) 
MALE 19 
FEMALE 13 
 
 
 
 
 
19 Males comprised the majority of the patients (59.4%) with only 13 females 
(40.6%) in the study group. 
 
 
 
SYMPTOMS: 
 
 NO. OF PATIENTS(n=32) 
SYMPTOMATIC 30 
INCIDENTAL DETECTION 2 
 
 
 
 
 
 
 
 
 
 
CLINICAL FEATURES: 
CLINICAL FEATURES 
NO OF CASES 
(n=30) 
PAIN ABDOMEN 21 
PALPABLE ABDOMINAL MASS 16 
GI BLEEDING(HEMATEMESIS/MALENA) 10 
PERFORATION 2 
INTESTINAL OBSTRUCTION 5 
 
 
Pain abdomen was the predominant symptom, seen in 21 patients. 16 patients 
had a palpable abdominal mass at the time of presentation. 10 patients presented 
with symptoms of GI tract bleeding (hematemesis/malena).  
Of the 7 patients presenting as acute emergency, 5 had features of intestinal 
obstruction, while 2 presented with perforation and peritonitis. 
RESCECTABILITY OF TUMOR: 
 
RESCECTABILITY OF 
TUMOR 
NO. OF PATIENTS(n=32) 
RESECTABLE 27 
UNRESECTABLE 5 
 
 
 
Out of 32 patients, 30 (94%) had resectable tumors. 5 patients had unresectable 
tumors.  
 
 
 
 
 METASTATIC DISEASE: 
 
LIVER METASTASIS NO. OF PATIENTS(n=32) 
ABSENT 30 
PRESENT 2 
 
 
Only 2 patients presented with liver metastasis both these patients also had 
unresectable disease. 
 
 
 
 
 
TUMOR LOCATION: 
 NO. OF PATIENTS(n=32) 
SMALL INTESTINE 14 
STOMACH 13 
EXTRAINTESTINAL  3 
ESOPHAGUS 1 
LARGE INTESTINE 1 
 
 
14 patients (43.7%) patients had primary disease in the small bowel. 13 patients 
(40.6%) presented with Gastric GIST. 3 patients had extraintestinal disease (2 
patients had the primary from the ileal mesentery and another patient developed 
an Omental GIST). 
One patient each had primary tumor localised to the esophagus (lower 1/3) and 
large intestine (caecum). 
 GASTRIC GISTs LOCATION: 
 
GASTRIC GISTs LOCATION NO. OF PATIENTS(n=13) 
PYLORUS 8 
BODY 3 
CARDIA 1 
FUNDUS 1 
 
 
 
Majority of the gastric GISTs were localised to the pylorus (8), followed by the 
body (3). One patient each had fundal and cardial GIST. 
 
 
 SURGICAL MANAGEMENT FOR GASTRIC GISTs: 
 
SURGERY NO. OF PATIENTS(n=13) 
PARTIAL GASTRECTOMY 7 
TOTAL GASTRECTOMY 3 
UNRESECTABLE 2 
 
 
 
The majority of patients with gastric GISTs underwent a partial gastretomy(7), 
while a total gastrectomy was performed for 3 patients. 2 patients were 
inoperable with liver metastsis, feeding jejunostomy was done in them, as they 
also had symptoms of gastric outlet obstruction. 
 
SMALL INTESTINAL GISTs LOCATION AND 
SURGICAL MANAGEMENT: 
 
SMALL INTESTINAL GISTs 
LOCATION 
NO. OF 
PATIENTS(n=14) 
ILEUM 9 
JEJUNUM 5 
 
 
Most of the small bowel GISTs were seen in the ileum (9), while 5 patients had 
jejunal GISTs. All 14 patients with small intestinal GISTs were operable, and 
Intestinal Resection/Anastamosis was done in all cases. 
 
 
 
 Figs. 18 Jejunal GIST before and after Resection/anastamosis 
 
 
 
 
 
 
 
SIZE OF PRIMARY TUMOR: 
SIZE OF GREATEST DIMENSION NO. OF PATIENTS(n=32) 
≤5cm 15 
>5cm, ≤10cm  12 
>10cm 5 
 
 
 
The majority of patients (15) had tumor size in the greatest dimension ≤5cm. 12 
patients had primary GIST size between 5-10 cm, while 5 patients had GISTs > 
10cm in size. The tumors studied showed wide variation in size, with the 
smallest measuring 2cm and the largest 28cm. 
Median size was 6 cm.  The largest GIST (28cm) was seen in the ileal 
mesentery. The tumor produced intestinal obstruction and was unresectable, 
however, debulking and intestinal resection/anastomosis was done. 
HISTOPATHOLOGICAL TYPES: 
 
HISTOPATHOLOGICAL 
TYPES 
NO. OF PATIENTS(n=32) 
SPINDLE 24 
EPITHELOID 5 
MIXED 3 
 
 
Majority of cases showed spindle cell type (75%). 5 cases showed epitheloid 
histopathology, while 2 were of the mixed variety. Both tumors associated with 
the mixed subtype were larger and more aggressive. Epitheloid tumors were 
more commonly seen in the stomach. 
 
 
STAGEWISE INCIDENCE: 
 
STAGE SIZE MITOTIC 
RATE 
NO. OF 
PATIENTS(n=32) 
1 ≤2cm ≤5/50HPF 1 
2 >2≤5cm ≤5/50HPF 13 
3a >5≤10cm ≤5/50HPF 7 
3b >10cm ≤5/50HPF 2 
4 ≤2cm >5/50HPF 0 
5 >2≤5cm >5/50HPF 1 
6a >5≤10cm >5/50HPF 5 
6b >10cm >5/50HPF 3 
 
 
Majority (40%) of patients were found to have prognostic stage 2 disease. 
However, 25% of all patients were found to have stage 6 disease. 
GRADING: 
 
GRADING NO. OF PATIENTS(n=32) 
LOW 13 
INTERMEDIATE 12 
HIGH 7 
 
 
 
Low and intermittent grade tumors were predominantly seen. All three cases of 
Extraintestinal GIST were found to be of high grade. 
 
 
 
 
NO. OF MITOSES: 
 
NO. OF MITOSES (PER 50 
HPF) 
NO. OF PATIENTS(n=32) 
<5/50hpf 23 
>5/50hpf 9 
 
 
 
Most (72%) of the tumors had favourable mitoses (<5/50hpf). All tumors with 
mixed histopathology had high number of mitoses. 
 
 
IMMUNOHISTOCHEMISTRY: 
All 32 cases of GIST studied were CD117 positive. 
DISCUSSION 
 
GIST is a rare and fairly newly baptized neoplasm and both Indian and 
international data about it is still evolving. 
 
AGE AND SEX DISTRIBUTION: 
The majority of patients in our study (65%) were above 50 years of age, with 
peak incidence between the 60-69 years of age (31%). The median age was 56. 
This corresponds well with international as well as Indian statistics.
36,72,77,78 
Male patients comprised 59.4% of all GIST cases and female patients the 
remainder in our study. This is similar to most international and studies. 
However Indian data suggests male preponderance.
72,78
 
 
PRESENTATION 
78% of all patients presented electively in the outpatient department, 22% 
presented as an acute emergency. When compared to international data, our 
study shows a slighty higher incidence in emergency presentation.
36
 Also, the 
number of GISTs presenting with unresectable disease was low (15%).The 
number of cases presenting with metastatic disease (6%) (To the liver) was also 
lower than most international studies.
36 
 
CLINICAL FEATURES: 
Our study showed that abdominal pain was the predominant symptom, seen in 
65% of all patients. GI bleeding was seen only in 10 cases (31%). However, 
most international studies show GI bleeding to be the most common clinical 
feature associated with GIST.
2,36
 Another Indian study also has shown 
abdominal pain as the predominant clinical feature in GISTs.
78 
 
Half of all patients had a palpable abdominal mass at the time of presentation, 
again a feature not seen in most American studies. Also, only 6% of all cases 
were incidentally detected. These deviations from international data may be 
explained by presentation late in the natural history of the disease among lower 
socio-economic groups (which comprise the majority of the studied population) 
in India, as is seen in cancers of the stomach and breast.
74,75
 
 
 
 
 
 
 
 
 
TUMOR LOCATION: 
Our study showed almost equal incidence of GIST in the small intestine 
(43.7%)  and stomach (40.6%) . This shows variance from most international 
studies, which state stomach as the most common organ involved in GIST.
2,13,36
 
However, our study correlates well with Indian data, which suggests equal 
incidence between small intestinal and gastric GISTs in the Indian 
population.
77,78 
9% of patients showed extraintestinal disease, involving the mesentery and 
omentum. This is higher than most international studies.
2,36
 Again, howevr, 
Indian studies have shown higher incidence of extraintestinal GISTs.
78 
 
SIZE OF PRIMARY TUMOR: 
46% of patients (15) had tumor size in the greatest dimension ≤5cm. 37% 
patients had primary GIST size between 5-10 cm, while 15% patients had 
GISTs > 10cm in size. This is on par with other international studies.
2,26,36 
 
 
 
 
 
HISTOPATHOLOGY 
Most cases showed spindle cell type (75%). 15% of cases showed epitheloid 
histopathology, while the remaider showed the mixed variety. This data is 
similar to international statstics.
26,36 
Low and intermittent grade tumors were predominantly seen.  
Most (72%) of the tumors had favourable mitoses (<5/50hpf). These findings 
are similar to international data. 
All 32 cases of GIST studied were CD117 positive. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
 
GIST in Indian population shows slight male preponderance. Also, GI bleeding 
as a chief presenting complaint, while not infrequent, is superseded by 
abdominal pain, which was the most common presenting complaint in our 
study. In most Indian series, including our study, small intestinal and stomach 
GISTs have similar incidence; also, extraintestinal GISTs appear to be more 
common in India. The incidence of metastatic disesase and unresectable disease 
also seems to be lower in the Indian population. Most gross and microscopic 
histopathological data Indian studies appear to be correlating well with 
international studies. 
 
 
 
 
 
 
 
 
 
 
 
